Alyson Haslam

Title(s)Research Data Analyst, Epidemiology & Biostatistics
SchoolSchool of Medicine
Address3333 California Street
San Francisco CA 94118
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis. Int J Cancer. 2025 Jan 30. Haslam A, Olivier T, Prasad V. PMID: 39887747.
      View in: PubMed   Mentions:
    2. The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma. Oncologist. 2024 Dec 24. Mohyuddin GR, Almasri J, Goodman A, Haslam A, Prasad V. PMID: 39719103.
      View in: PubMed   Mentions:    Fields:    
    3. Cross-sectional evaluation of medical reversals among National Institute of Health guideline practices implemented during the COVID-19 pandemic: how often did experts err in a time of crisis? BMJ Open. 2024 Dec 20; 14(12):e085210. Kacew AJ, Haslam A, Prasad V, Cifu AS. PMID: 39806706; PMCID: PMC11667299.
      View in: PubMed   Mentions:    Fields:    
    4. Trend of sales revenue by year for top selling cancer drugs in the US and the effect of loss of market exclusivity. J Cancer Policy. 2024 Dec 09; 43:100533. Kim MS, Haslam A, Prasad V. PMID: 39662670.
      View in: PubMed   Mentions:    Fields:    
    5. Financial conflicts among physician speakers at the April 12, 2024 Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma? J Cancer Policy. 2024 Dec 06; 43:100529. Carr NJ, Haslam A, Prasad V. PMID: 39647696.
      View in: PubMed   Mentions:    Fields:    
    6. Reply to: The Value of Offering Oncofertility Counseling in Young Patients With Newly Diagnosed Cancer Is Unquestionable. JCO Oncol Pract. 2024 Nov 22; OP2400783. Prasad V, Haslam A. PMID: 39576949.
      View in: PubMed   Mentions:    Fields:    
    7. Analysis of 810 tweets from 25 unofficial ASCO representatives (Featured Voices) at ASCO 2024. J Cancer Policy. 2024 Dec; 42:100519. Stratton O, Haslam A, Prasad V. PMID: 39522635.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Are Blood-Based Cancer Screening Tests Ready for Primetime? Am J Med. 2024 Nov 08. Prasad V, Haslam A, Olivier T. PMID: 39522669.
      View in: PubMed   Mentions:    Fields:    
    9. Spending on anticancer drugs among Medicare beneficiaries: Analyzing predictors of drug expenditures. J Cancer Policy. 2024 Dec; 42:100509. Nee A, Haslam A, Prasad V. PMID: 39419282.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more. BMJ Oncol. 2024; 3(1):e000364. Olivier T, Haslam A, Ochoa D, Fernandez E, Prasad V. PMID: 39886154; PMCID: PMC11557723.
      View in: PubMed   Mentions:
    11. Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial. Am J Hematol. 2024 Dec; 99(12):2392-2394. Srinivasan N, Olivier T, Haslam A, Prasad V. PMID: 39340218.
      View in: PubMed   Mentions:    Fields:    
    12. A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019. Open Forum Infect Dis. 2024 Sep; 11(9):ofae497. Haslam A, Prasad V. PMID: 39286035; PMCID: PMC11403474.
      View in: PubMed   Mentions: Translation:CTClinical Trials
    13. Recall of ibrutinib and issues with therapeutic approval. BMJ Oncol. 2024; 3(1):e000418. Lipfert C, Kim MS, Haslam A, Prasad VK. PMID: 39886132; PMCID: PMC11347682.
      View in: PubMed   Mentions:
    14. Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review. JAMA Oncol. 2024 Aug 01; 10(8):1055-1059. Olivier T, Haslam A, Prasad V. PMID: 38900419; PMCID: PMC11190827.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. The landscape of checkpoint inhibitors in oncology. Eur J Cancer. 2024 Sep; 209:114240. Haslam A, Kim MS, Elbaz J, Prasad V. PMID: 39084136.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. Lancet Oncol. 2024 Aug; 25(8):979-988. Jenei K, Gentilini A, Haslam A, Prasad V. PMID: 39004098.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Cancer Therapy, Gonadal Function, and Fertility Preservation: Narrative Review. JCO Oncol Pract. 2024 Dec; 20(12):1580-1587. Eden CO, Haslam A, Prasad V. PMID: 38954787.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. Eur J Cancer. 2024 Aug; 207:114192. Haslam A, Ranganathan S, Prasad V, Olivier T. PMID: 38959677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. A novel framework to assess haematology and oncology registration trials: The THEOREMM project. Eur J Clin Invest. 2024 Oct; 54(10):e14267. Olivier T, Haslam A, Burke P, Boutron I, Naudet F, Ioannidis JPA, Prasad V. PMID: 38934596.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Publication of observational studies making claims of causation over time. Contemp Clin Trials Commun. 2024 Aug; 40:101327. Haslam A, Prasad V. PMID: 39036556; PMCID: PMC11259777.
      View in: PubMed   Mentions:
    21. Social media engagement of supportive care publications in oncology. J Cancer Policy. 2024 Sep; 41:100491. Ranganathan S, Benjamin DJ, Haslam A, Prasad V. PMID: 38852671.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications. Clin Ther. 2024 Jun; 46(6):e107-e113. Hunter Hall R, Wright CL, Hughes GK, Peña AM, Ladd C, Gardner B, McIntire R, Ferrell M, Rubenstein J, Tuia J, Haslam A, Prasad V, Vassar M. PMID: 38825553.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Long COVID clinics and services offered by top US hospitals: an empirical analysis of clinical options as of May 2023. BMC Health Serv Res. 2024 May 30; 24(1):684. Haslam A, Prasad V. PMID: 38816726; PMCID: PMC11138016.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    24. Health-related quality of life in trials with high rates of early censoring: Caution advised. Eur J Cancer. 2024 Jul; 205:114105. Olivier T, Haslam A, Prasad V. PMID: 38718724.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials. Cancer Med. 2024 May; 13(9):e7130. Khan A, Khan H, Hughes GK, Ladd C, McIntire R, Gardner B, Peña AM, Schoutko A, Tuia J, Minley K, Haslam A, Prasad V, Vassar M. PMID: 38698690; PMCID: PMC11066501.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas. J Cancer Policy. 2024 Jun; 40:100476. Zugman M, Haslam A, Prasad V. PMID: 38588795.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023). Cancer Med. 2024 Apr; 13(8):e7190. Elbaz J, Haslam A, Prasad V. PMID: 38659418; PMCID: PMC11043668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials. BMJ Oncol. 2024; 3(1):e000229. Dennis B, Bratten C, Hughes GK, Peña AM, McIntire R, Ladd C, Gardner B, Nowlin W, Livingston R, Tuia J, Haslam A, Prasad V, Vassar M. PMID: 39886178; PMCID: PMC11234991.
      View in: PubMed   Mentions:
    29. Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis. Eur J Cancer. 2024 May; 202:114019. Lam M, Olivier T, Haslam A, Tuia J, Prasad V. PMID: 38522156.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review. Target Oncol. 2024 Mar; 19(2):161-173. Crotty P, Kari K, Hughes GK, Ladd C, McIntire R, Gardner B, Peña AM, Ferrell S, Tuia J, Cohn J, Haslam A, Prasad V, Vassar M. PMID: 38466535.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. COVID-19 vaccines: history of the pandemic's great scientific success and flawed policy implementation. Monash Bioeth Rev. 2024 Jun; 42(1):28-54. Prasad V, Haslam A. PMID: 38459404; PMCID: PMC11368972.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    32. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials. Cancer Med. 2024 Mar; 13(5):e7049. Benjamin DJ, Haslam A, Prasad V. PMID: 38491813; PMCID: PMC10943275.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Justification for unequal allocation ratios in clinical trials: A scoping review. Contemp Clin Trials. 2024 04; 139:107484. Nay J, Haslam A, Prasad V. PMID: 38431132.
      View in: PubMed   Mentions:    Fields:    
    34. Estimation of eligibility for and response to CAR-T therapy in the United States. Blood Adv. 2024 02 27; 8(4):1032-1036. Haslam A, Hoeg TB, Prasad V. PMID: 38039516; PMCID: PMC10920105.
      View in: PubMed   Mentions: 2     Fields:    
    35. Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops. Eur J Clin Invest. 2024 Jun; 54(6):e14184. Miller SL, Haslam A, Prasad V. PMID: 38407501.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm-benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiol Infect. 2024 Feb 16; 152:e51. Høeg TB, Haslam A, Prasad V. PMID: 38361448; PMCID: PMC11022251.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    37. Discrepancies in Estimating Excess Death by Political Party Affiliation During the COVID-19 Pandemic. JAMA Intern Med. 2024 Jan 01; 184(1):118-119. Dasaro C, Haslam A, Prasad V. PMID: 38010692.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    38. Assessing patient burden and benefit: A decade of cabozantinib clinical trials. Int J Cancer. 2024 Apr 15; 154(8):1464-1473. Hughes GK, Sajjadi NB, Gardner B, Ramoin JK, Tuia J, Haslam A, Prasad V, Vassar M. PMID: 38108216.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy. J Cancer Policy. 2024 Mar; 39:100462. Ranganathan S, Haslam A, Tuia J, Prasad V. PMID: 38061492.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Cancer Drug Price and Novelty in Mechanism of Action. JAMA Netw Open. 2023 12 01; 6(12):e2347006. Miljkovic MD, Tuia J, Olivier T, Haslam A, Prasad V. PMID: 38079171; PMCID: PMC10714245.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Systematic Review and Meta-Analysis of Randomized Trials Testing Interventions to Reduce Physician Burnout. Am J Med. 2024 03; 137(3):249-257.e1. Haslam A, Tuia J, Miller SL, Prasad V. PMID: 37890569.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity. JAMA Netw Open. 2023 10 02; 6(10):e2338612. Olivier T, Haslam A, Tuia J, Prasad V. PMID: 37883087; PMCID: PMC10603498.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    43. An Analysis of Studies Pertaining to Masks in Morbidity and Mortality Weekly Report: Characteristics and Quality of Studies through 2023. Am J Med. 2024 02; 137(2):154-162.e1. Høeg TB, Haslam A, Prasad V. PMID: 37777144.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. Flu advice in the U.S. news media changed during the COVID-19 pandemic but not the evidence. Eur J Epidemiol. 2023 Oct; 38(10):1115-1117. Brown E, Haslam A, Prasad V. PMID: 37697025.
      View in: PubMed   Mentions:    Fields:    
    45. Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer. BMC Med. 2023 09 08; 21(1):344. Olivier T, Haslam A, Prasad V. PMID: 37679732; PMCID: PMC10485976.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs. JAMA Oncol. 2023 09 01; 9(9):1238-1244. Lam M, Olivier T, Haslam A, Tuia J, Prasad V. PMID: 37471095; PMCID: PMC10360002.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    47. Evidence Base for Health Care Strategies to Protect Vulnerable Patients During the COVID-19 Pandemic. JAMA Oncol. 2023 08 01; 9(8):1150. Haslam A, Prasad V. PMID: 37261802.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    48. Multiple myeloma: challenges with deciding the optimal sequencing strategy. Front Pharmacol. 2023; 14:1231720. Walia A, Haslam A, Tuia J, Prasad V. PMID: 37465528; PMCID: PMC10350499.
      View in: PubMed   Mentions:
    49. Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use. Trials. 2023 Jun 03; 24(1):373. Prasad V, Kim MS, Haslam A. PMID: 37270500; PMCID: PMC10239129.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022. J Cancer Policy. 2023 09; 37:100426. Olivier T, Smith CEP, Haslam A, Addeo A, Prasad V. PMID: 37270063.
      View in: PubMed   Mentions: 1     Fields:    
    51. Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals. JAMA Netw Open. 2023 06 01; 6(6):e2318877. Haslam A, Tuia J, Prasad V. PMID: 37358855; PMCID: PMC10293908.
      View in: PubMed   Mentions:    Fields:    
    52. Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020. BMC Cancer. 2023 May 17; 23(1):448. Olivier T, Haslam A, Prasad V. PMID: 37198564; PMCID: PMC10189952.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. Profile of the Oncology Physician Workforce and the Characteristics of Attrition. JCO Oncol Pract. 2023 07; 19(7):465-472. Tuia J, Haslam A, Prasad V. PMID: 37186885.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Cross-sectional analysis of open payments for physicians at designated hemophilia centers in the US (2018-2020). Thromb Res. 2023 07; 227:40-44. Haslam A, Prasad V. PMID: 37210957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis. JAMA Intern Med. 2023 05 01; 183(5):435-441. Banerjee T, Kim MS, Haslam A, Prasad V. PMID: 36939665; PMCID: PMC10028543.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    56. Is financial toxicity captured in quality of life assessments in oncology randomized clinical trials? J Cancer Policy. 2023 06; 36:100423. Olivier T, Haslam A, Prasad V. PMID: 37075841.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    57. The definition of long COVID used in interventional studies. Eur J Clin Invest. 2023 Aug; 53(8):e13989. Haslam A, Olivier T, Prasad V. PMID: 36964995.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    58. Omission of Critical Information From Clinical Trial Reports-What to Do About Uninterpretable Results. JAMA Oncol. 2023 04 01; 9(4):459-460. Olivier T, Haslam A, Prasad V. PMID: 36821106.
      View in: PubMed   Mentions:    Fields:    
    59. The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review. J Cancer Res Clin Oncol. 2023 Aug; 149(10):7355-7362. Bhatt A, Haslam A, Prasad V. PMID: 36928160; PMCID: PMC10374733.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    60. The response rate by tumour type for tissue-agnostic approved drugs. Eur J Cancer. 2023 05; 184:117-119. Haslam A, Prasad V. PMID: 36913833.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Design, power, and alpha levels in randomized phase II oncology trials. ESMO Open. 2023 02; 8(1):100779. Haslam A, Olivier T, Prasad V. PMID: 36736072; PMCID: PMC10024120.
      View in: PubMed   Mentions: 1  Translation:Humans
    62. Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals. JAMA Netw Open. 2023 02 01; 6(2):e2254405. Buck E, Haslam A, Tuia J, Prasad V. PMID: 36723940; PMCID: PMC9892954.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. Comparability of Control and Comparison Groups in Studies Assessing Long COVID. Am J Med. 2025 Jan; 138(1):148-152.e3. Haslam A, Prasad V. PMID: 36708796; PMCID: PMC9912142.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    64. Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer. 2023 Jan 13; 23(1):46. Haslam A, Olivier T, Tuia J, Prasad V. PMID: 36639625; PMCID: PMC9840247.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    65. Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival? Transl Oncol. 2023 Feb; 28:101591. Olivier T, Haslam A, Prasad V. PMID: 36577165; PMCID: PMC9803768.
      View in: PubMed   Mentions: 3  
    66. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023 03; 200(5):587-594. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. PMID: 36495317.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    67. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020. JAMA Intern Med. 2022 12 01; 182(12):1319-1320. Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V. PMID: 36315136; PMCID: PMC9623474.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    68. Financial conflicts of interest of OncoAlert: An informal oncology professional network. J Cancer Policy. 2022 12; 34:100369. Powell K, Kakkilaya A, Haslam A, Prasad V. PMID: 36396090.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    69. A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. Eur J Cancer. 2023 01; 178:227-233. Haslam A, Olivier T, Tuia J, Prasad V. PMID: 36493558.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    70. Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. N Engl J Med. 2022 10 20; 387(16):1527. Haslam A, Prasad V. PMID: 36260800.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022 10 07; 12(10):e064458. Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. PMID: 36207035; PMCID: PMC9558788.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    72. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis. J Cancer Policy. 2022 12; 34:100363. Prasad V, Olivier T, Chen EY, Haslam A. PMID: 36162749.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    73. FDA validation of surrogate endpoints in oncology: 2005-2022. J Cancer Policy. 2022 12; 34:100364. Walia A, Haslam A, Prasad V. PMID: 36155118.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    74. Characteristics of Facebook's third-party medical fact checkers. Digit Health. 2022 Jan-Dec; 8:20552076221120318. Haslam A, Prasad V. PMID: 36003316; PMCID: PMC9393657.
      View in: PubMed   Mentions:
    75. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. Eur J Cancer. 2022 09; 172:349-356. Olivier T, Haslam A, Prasad V. PMID: 35830842.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Eventual success rate and predictors of success for oncology drugs tested in phase I trials. Int J Cancer. 2023 01 15; 152(2):276-282. Haslam A, Olivier T, Powell K, Tuia J, Prasad V. PMID: 35716142.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    77. Impact of a Farm-to-School Nutrition and Gardening Intervention for Native American Families from the FRESH Study: A Randomized Wait-List Controlled Trial. Nutrients. 2022 Jun 23; 14(13). Taniguchi T, Haslam A, Sun W, Sisk M, Hayman J, Jernigan VBB. PMID: 35807781; PMCID: PMC9268191.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    78. Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials. JAMA Netw Open. 2022 05 02; 5(5):e2212327. Ahmed N, Vengalasetti Y, Haslam A, Prasad V. PMID: 35576006; PMCID: PMC9112068.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm? ESMO Open. 2022 06; 7(3):100480. Haslam A, Olivier T, Thawani R, Prasad V. PMID: 35468562; PMCID: PMC9271471.
      View in: PubMed   Mentions: 1  Translation:Humans
    80. Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident. Eur J Emerg Med. 2022 04 01; 29(2):142-143. Herrera-Perez D, Gill J, Haslam A, Crain T, Klossner Q, Prasad V. PMID: 35210379.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    81. Targeted therapy in lung cancer: Are we closing the gap in years of life lost? Cancer Med. 2022 09; 11(18):3417-3424. Benjamin DJ, Haslam A, Gill J, Prasad V. PMID: 35315222; PMCID: PMC9487872.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    82. Characteristics of oncology podcasts: Attitudes, speakers, conflicts. J Cancer Policy. 2022 06; 32:100329. Akman EG, Powell K, Haslam A, Prasad V. PMID: 35560266.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    83. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. Int J Cancer. 2022 06 01; 150(11):1905-1910. Kim MS, Xu A, Haslam A, Prasad V. PMID: 35182072.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    84. Design and Methods of a Participatory Healthy Eating Intervention for Indigenous Children: The FRESH Study. Front Public Health. 2022; 10:790008. Blue Bird Jernigan V, Taniguchi T, Haslam A, Williams MB, Maudrie TL, Nikolaus CJ, Wetherill MS, Jacob T, Love CV, Sisson S. PMID: 35296044; PMCID: PMC8920553.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    85. Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. Eur J Cancer. 2022 03; 164:95-104. Maniar A, Haslam A, Prasad V. PMID: 35182927.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    86. The effect of food prescription programs on chronic disease management in primarily low-income populations: A systematic review and meta-analysis. Nutr Health. 2022 Sep; 28(3):389-400. Haslam A, Gill J, Taniguchi T, Love C, Jernigan VB. PMID: 35108144; PMCID: PMC10150796.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    87. Development and Implementation of a Hybrid Online and In-Person Food Sovereignty and Nutrition Education Curriculum for Native American Parents: The FRESH Study. Health Educ Behav. 2023 06; 50(3):430-440. Haslam A, Love C, Taniguchi T, Williams MB, Wetherill MS, Sisson S, Weedn AE, Jacob T, Blue Bird Jernigan V. PMID: 34991400; PMCID: PMC9981305.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    88. Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials. JAMA Netw Open. 2022 01 04; 5(1):e2144770. Olivier T, Haslam A, Prasad V. PMID: 35061042; PMCID: PMC8783268.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    89. How Often do Medical Specialties Question the Practices that They Perform? An Empirical, Cross-Sectional Analysis of the Published Literature. Inquiry. 2022 Jan-Dec; 59:469580211061034. Haslam A, Powell K, Prasad V. PMID: 35322719; PMCID: PMC8961376.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    90. Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. JAMA Intern Med. 2022 01 01; 182(1):76-78. Kim MS, Cai J, Maniar A, Kartika T, Haslam A, Prasad V. PMID: 34491275; PMCID: PMC8424524.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    91. A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. J Cancer Policy. 2022 03; 31:100319. Prasad V, Haslam A, Tuia J. PMID: 35559871.
      View in: PubMed   Mentions:    Fields:    
    92. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Netw Open. 2021 12 01; 4(12):e2138793. Olivier T, Haslam A, Prasad V. PMID: 34905002; PMCID: PMC8672232.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    93. Artificial intelligence and magnetic resonance imaging may not make cancer screening better. J Cancer Policy. 2022 03; 31:100314. Powell K, Kim MS, Haslam A, Prasad V. PMID: 35559866.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    94. The frequency of assessment of progression in randomized oncology clinical trials. Cancer Rep (Hoboken). 2022 07; 5(7):e1527. Haslam A, Gill J, Prasad V. PMID: 34821077; PMCID: PMC9327664.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    95. Overall survival for oncology drugs approved for genomic indications. Eur J Cancer. 2022 01; 160:175-179. Haslam A, Kim MS, Prasad V. PMID: 34819251.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    96. Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. JAMA Netw Open. 2021 11 01; 4(11):e2135123. Haslam A, Lythgoe MP, Greenstreet Akman E, Prasad V. PMID: 34792592; PMCID: PMC8603079.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    97. An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence Based? Am J Med. 2022 02; 135(2):179-183. Powell K, Haslam A, Prasad V. PMID: 34678212.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. An Analysis of 5 Years of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. Dig Dis Sci. 2022 06; 67(6):2011-2018. Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B. PMID: 34463882.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. BMC Cancer. 2021 Aug 03; 21(1):889. Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V. PMID: 34344325; PMCID: PMC8336285.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    100. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. J Clin Epidemiol. 2021 11; 139:80-86. Olivier T, Haslam A, Prasad V. PMID: 34311054.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    101. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Ann Oncol. 2021 07; 32(7):926-932. Haslam A, Kim MS, Prasad V. PMID: 33862157.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    102. Perceived Environments and Physical Activity Among American Indian Adults Living in Oklahoma: The THRIVE Study. Prog Community Health Partnersh. 2021; 15(3):267-268. Haslam A, Taniguchi T, Love C, Jacob T, Cannady TK, Standridge J, Grammar M, Fox J, Spiegel J, Crain T, Jernigan VBB. PMID: 37934415.
      View in: PubMed   Mentions:    Fields:    
    103. Perceived Environments and Physical Activity Among American Indian Adults Living in Oklahoma: The THRIVE Study. Prog Community Health Partnersh. 2021; 15(3):285-296. Haslam A, Taniguchi T, Love C, Jacob T, Cannady TK, Standridge J, Grammar M, Fox J, Spiegel J, Crain T, Jernigan VBB. PMID: 37934418.
      View in: PubMed   Mentions:    Fields:    
    104. The response rate of alternative treatments for drugs approved on the basis of response rate. Int J Cancer. 2021 02 01; 148(3):713-722. Haslam A, Gill J, Prasad V. PMID: 32700797.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    105. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. JAMA Intern Med. 2020 06 01; 180(6):912-914. Chen EY, Haslam A, Prasad V. PMID: 32338703; PMCID: PMC7186918.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    106. Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Sci OA. 2020 May 25; 6(8):FSO600. Maldonado EB, Parsons S, Chen EY, Haslam A, Prasad V. PMID: 32983564; PMCID: PMC7491026.
      View in: PubMed   Mentions: 11  
    107. Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. JAMA Intern Med. 2020 05 01; 180(5):797-799. Gill J, Haslam A, Crain T, Herrera-Perez D, Prasad V. PMID: 32202604; PMCID: PMC7091392.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    108. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. J Natl Compr Canc Netw. 2020 04; 18(4):428-433. Hazim A, Mills G, Prasad V, Haslam A, Chen EY. PMID: 32259790.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    109. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Netw Open. 2020 03 02; 3(3):e200423. Haslam A, Gill J, Prasad V. PMID: 32150268; PMCID: PMC7063495.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    110. Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Netw Open. 2020 03 02; 3(3):e200363. Haslam A, Herrera-Perez D, Gill J, Prasad V. PMID: 32129865; PMCID: PMC7057133.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    111. Medical Reversals in Family Practice: A Review. Curr Ther Res Clin Exp. 2020; 92:100579. Haslam A, Livingston C, Prasad V. PMID: 32180846; PMCID: PMC7063107.
      View in: PubMed   Mentions: 2     Fields:    
    112. Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions. Mayo Clin Proc. 2020 02; 95(2):424-426. Haslam A, Gill J, Prasad V. PMID: 32029095.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough? J Natl Compr Canc Netw. 2020 02; 18(2):161-167. Haslam A, Gill J, Prasad V. PMID: 32023529.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    114. Medical reversals in low- and middle-income countries. Int J Health Plann Manage. 2020 Mar; 35(2):631-638. Haslam A, Prasad V, Livingston C. PMID: 31710144.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    115. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Netw Open. 2019 11 01; 2(11):e1916091. de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V. PMID: 31755953; PMCID: PMC6902826.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    116. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. Elife. 2019 06 11; 8. Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, Hayes M, Morgan D, Cifu AS, Prasad V. PMID: 31182188; PMCID: PMC6559784.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    117. Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice? Mayo Clin Proc. 2019 06; 94(6):951-956. Chapa J, Haslam A, Prasad V. PMID: 31171133.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    118. Confirmatory Trials for Drugs Approved on a Single Trial. Circ Cardiovasc Qual Outcomes. 2019 06; 12(6):e005494. Haslam A, Prasad V. PMID: 31137954.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    119. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 05 03; 2(5):e192535. Haslam A, Prasad V. PMID: 31050774; PMCID: PMC6503493.
      View in: PubMed   Mentions: 586     Fields:    Translation:Humans
    120. Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. Am J Med. 2019 06; 132(6):718-721. Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V. PMID: 30639552.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    121. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer. 2019 01; 106:196-211. Haslam A, Hey SP, Gill J, Prasad V. PMID: 30528804.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    122. Survey to Assess Interest in a Mindfulness Intervention at a Midwifery and Women's Health Clinic. Holist Nurs Pract. 2018 Sep/Oct; 32(5):261-267. Haslam A, Salm Ward T, Wagner Robb S. PMID: 30113960.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    123. Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose: How Do We Know That? Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004886. Haslam A, Prasad V. PMID: 29991647.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    124. Association between dietary pattern scores and the prevalence of colorectal adenoma considering population subgroups. Nutr Diet. 2018 04; 75(2):167-175. Haslam A, Wagner Robb S, Hébert JR, Huang H, Ebell MH. PMID: 29280253.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    Alyson's Networks
    Concepts (264)
    Derived automatically from this person's publications.
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _